Orforglipron
The oral, non-peptide GLP-1 pill — real Phase 2/3 data, not yet approved, and easy to counterfeit.
Evidence tier: B (positive published Phase 2 randomized trials; Phase 3 program ongoing; not yet approved) · Regulatory status in Canada: not approved — investigational · Community risk profile: moderate-to-high — an oral, non-injected incretin will lower the barrier to grey-market use, and no approved supply exists yet.
B
What it is
Orforglipron is an investigational oral, small-molecule GLP-1 receptor agonist from Eli Lilly. Unlike semaglutide/tirzepatide (injected peptides), it's a pill — and being a small molecule, it doesn't need the refrigeration or injection that peptides do. That combination is why it's watched as a potential mass-market shift in the GLP-1 space.
What People Use it For
Investigational: type 2 diabetes and obesity, in trials.
Community (emerging): anticipation more than established use — an oral GLP-1 is expected to draw people who won't inject. Grey-market interest tends to run ahead of approval, so it belongs on the watchlist now.
What The Evidence Shows
Tier B — promising, published, incomplete:
Obesity: A Phase 2 randomized trial reported significant weight loss (Wharton et al., NEJM 2023).
Type 2 diabetes: A Phase 2 trial showed meaningful glucose-lowering and weight effects (Frias et al., Lancet2023).
Phase 3 is ongoing; there is no approval yet and long-term outcome/safety data are not complete.
Honest framing: the trials are legitimate and the signal is real — but this is Phase 2-to-3, not an approved drug. As with retatrutide, "promising oral GLP-1" is exactly where enthusiasm outruns the completed evidence.
Regulatory Status - Canada
Not approved by Health Canada (or elsewhere) — orforglipron is investigational. There is no legal approved supply for personal use. As with retatrutide, this is a stronger caution than for the approved injectables: there is no approved product at all yet, so any grey-market "orforglipron" is unapproved and unverified.
Risks & Red Flags
From trials: GI effects (nausea, vomiting, diarrhea, constipation), dose- and titration-dependent — the incretin-class pattern.
Incompletely known: without completed Phase 3 and long-term data, the full safety profile isn't established — a data gap, not reassurance.
Grey-market-specific: self-dosing an investigational oral drug from unverified sources with no approved dosing guidance.
Sourcing red flags
No approved manufacturer exists, so any product sold now is unapproved and unverified.
Oral products are not inherently safer to source than injectables — identity and dose are still unconfirmed (see glossary; "99% purity" ≠ identity or dose).
Expect slang/renaming to appear as it gains attention (see glossary).
The Honest Bottom Line
Orforglipron is the most clinically advanced compound on this page that you still can't get legitimately: it's a small-molecule (pill, not injection) GLP-1 agonist with positive Phase 2 and reported Phase 3 results, on a real path to approval. The evidence is genuinely encouraging — Tier B because approval and long-term outcome data aren't in yet.
Because it's an oral small molecule rather than a peptide, the community assumes it's simpler and safer to source — which is exactly backwards. A pill is trivially easy to fake, and a gray-market "orforglipron" tablet has no manufacturer, no dose verification, and no reason to trust the label. Wait for the approved product.
How To Lower Your Risk
Understand the tier honestly: Phase 2-to-3 and unapproved. The weight/glucose effects are real in trials; that isn't the same as safe for unsupervised personal use.
"It's a pill" is not a safety upgrade over injectables when it's unapproved and unverified.
There is no approved source in Canada — if considering it, third-party identity + quantity testing is the minimum.
Tell a clinician (see clinician page); an oral incretin still interacts with diabetes medication and carries hypoglycemia risk in combination.
Sources
Wharton S, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (Phase 2). N Engl J Med.2023. doi:10.1056/NEJMoa2302392
Frias JP, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes (Phase 2). Lancet. 2023. doi:10.1016/S0140-6736(23)01302-8
DOIs verified via CrossRef for this project. COI note: trials sponsored by Eli Lilly — disclosed, not disqualifying.
Substrate is an independent educational harm-reduction resource. It is not medical, legal, or regulatory advice, and it is not a substitute for a licensed clinician. Compounds discussed are largely unapproved in Canada; nothing here endorses their use. Confirm anything health-related with a qualified professional. Built by a medical-sciences student — not a seller and not a clinic.